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Abstract
Background Muscle ring ﬁnger 1 (MuRF1) is a muscle-speciﬁc ubiquitin E3 ligase activated during clinical conditions associ-
ated with skeletal muscle wasting. Yet, there remains a paucity of therapeutic interventions that directly inhibit MuRF1
function, particularly in vivo. The current study, therefore, developed a novel compound targeting the central coiled coil do-
main of MuRF1 to inhibit muscle wasting in cardiac cachexia.
Methods We identiﬁed small molecules that interfere with the MuRF1–titin interaction from a 130 000 compound screen
based on Alpha Technology. A subset of nine prioritized compounds were synthesized and administrated during conditions
of muscle wasting, that is, to C2C12 muscle cells treated with dexamethasone and to mice treated with monocrotaline to
induce cardiac cachexia.
Results The nine selected compounds inhibited MuRF1–titin complexation with IC50 values <25 μM, of which three were
found to also inhibit MuRF1 E3 ligase activity, with one further showing low toxicity on cultured myotubes. This last com-
pound, EMBL chemical core ID#704946, also prevented atrophy in myotubes induced by dexamethasone and attenuated ﬁbre
atrophy and contractile dysfunction in mice during cardiac cachexia. Proteomic and western blot analyses showed that stress
pathways were attenuated by ID#704946 treatment, including down-regulation of MuRF1 and normalization of proteins asso-
ciated with apoptosis (BAX) and protein synthesis (elF2B-delta). Furthermore, actin ubiquitinylation and proteasome activity
was attenuated.
Conclusions We identiﬁed a novel compound directed to MuRF1’s central myoﬁbrillar protein recognition domain. This
compound attenuated in vivo muscle wasting and contractile dysfunction in cardiac cachexia by protecting de novo protein
synthesis and by down-regulating apoptosis and ubiquitin-proteasome-dependent proteolysis.
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Introduction
Skeletal muscle wasting is manifested under a variety of clin-
ical conditions, including chronic heart failure, pulmonary
hypertension, mechanical ventilation, cancer, immobilization,
and sepsis. The loss of muscle mass (i.e. atrophy), which
occurs in both limb and respiratory muscles, plays a critical
role in skeletal muscle weakness and respiratory complica-
tions observed in many patients, which, in turn, exacerbates
symptoms and prognosis.1 The underlying mechanisms of
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muscle atrophy include the activation of so-called atrogins,
leading to an enhanced degradation of proteins via the
autophagosome and ubiquitin-proteome system2–5 with mus-
cle ring ﬁnger 1 (MuRF1) believed to provide a key step in the
transfer of multi-ubiquitinated muscle proteins to the latter
system for degradation, respectively.6 Consistent with the
view that MuRF1 acts as an atrogin, its expression is inti-
mately associated with muscle wasting in numerous clinical
conditions (as reviewed in Bodine and Baehr2) or following
exposure to pharmacological treatments (e.g. glucocorti-
coids, inﬂammatory cytokines, reactive oxygen species7–10),
while its gene inactivation confers partial resistance to mus-
cle wasting conditions.7,8,11,12 Therefore, several approaches
have attempted to down-regulate MuRF1 activity therapeuti-
cally, either directly in vitro via targeted inhibition of MuRF1
by a muscle-speciﬁc small molecule13 and adenoviral knock-
downs14,15 or indirectly in vivo via exercise training16 or anti-
oxidant administration17, which resulted in a signiﬁcant
reduction in muscle wasting.
Here, we performed a high-throughput screen based on Al-
pha Technology to identify compounds that inhibit the previ-
ously documented interaction between MuRF1 and titin.18
Our earlier studies assigned MuRF1’s interaction with muscle
proteins to a central coiled coil domain (‘MuRF1 central’).19,20
Therefore, we hypothesized that it might be beneﬁcial to in-
hibit the recognition of muscle proteins by this MuRF1 cen-
tral domain, thereby maintaining its basal expression level
and E3 ligase activity that resides in MuRF1’s N-terminal ring
ﬁnger domain. This approach identiﬁed almost 100 com-
pounds from the EMBL in-house library that inhibit the
titin–MuRF1 complex formation in vitro (for a prototype of
this screening chemistry, refer to Labeit et al.21). From the to-
tal of about 100 hits of the high-throughput screen, one com-
pound has been characterized here in detail because of its
low toxicity on cultured cells and its ability to inﬂuence mus-
cle atrophy and dysfunction in an animal model of cardiac ca-
chexia. Overall, our data suggest that this novel compound
EMBL ID#704946 directed to MuRF1 central attenuated
in vivo muscle wasting and contractile dysfunction in cardiac
cachexia by mechanisms that involved a protection of muscle
protein de novo synthesis and a down-regulation in
apoptosis.
Methods and materials
Identiﬁcation of MuRF1 central-directed
compounds
Small-molecule screens were performed as previously
described,21 as based upon our previous MuRF1 and titin
interaction studies that identiﬁed the MuRF1 coiled coil do-
main to interact with titin A168-170.19,20 These interacting
fragments were expressed as GST and His6 fusion proteins
so that complex formation could be monitored with glutathi-
one donor and nickel chelate (Ni-NTA) acceptor beads,
respectively, in an AlphaScreen assay.22 For this, 125 nM
GST-Murf1 and 250 nM His-tagged titin were combined in
screening buffer (PBS, 1 mM DTT, 0.05% Tween 20) and
pre-incubated for 60 min in the presence of compounds or
under mock control conditions [dimethyl sulfoxide (DMSO)].
Afterwards, 5 μg/mL glutathione-coated donor and Ni-NTA-
coated acceptor beads were added. Following 60 min of incu-
bation, alpha signals were recorded using an EnVision™ plate
reader (PerkinElmer Life Sciences). In the primary screen,
compounds from the 130 000 compound encompassing
EMBL library were tested at a ﬁnal concentration of 40 μM.
Reordered compounds were veriﬁed by a concentration-
response experiment using an 11-fold 1:1 serial dilution
starting at 200 μM. The serially diluted compounds were also
tested as an additional technical control in a de-selection as-
say with 20 nM GSTHis, a fusion protein containing both an
N-terminal GST tag and a C-terminal His tag. Taken together,
our survey of the 130 000 compound-encompassing in-house
EMBL library identiﬁed a total of 79 molecules with
IC50 < 25 μmol/L for the MuRF1–titin interaction. Com-
pounds were next assessed for effects on MuRF1 E3 ligase ac-
tivity directed to titin or to MuRF1 itself (self-ubiquitination).
For this, respective compounds were added to an assay con-
taining 75 nmol/L UBE1 (Boston Biochem), 1 μmol/L UbcH5c
(Boston Biochem), 100 μmol/L ubiquitin, 4 mmol/L ATP, 100
nmol/L titin A168-170. Reactions were started by the addi-
tion of 220 nmol/L MuRF1, followed by 1 h at 37°C SDS PAGE
and western blot analysis with MuRF1 and titin-speciﬁc anti-
bodies. All reactions also included 5% DMSO. Three com-
pounds were then selected based on ubiquitination
patterns and thereafter synthesized at a 10 g scale by En-
amine (Kiev, Ukraine). For subsequent experiments in cells
or mice, compounds were either dissolved at 10 mmol/L in
DMSO and added to the culture medium 0.01 to 50 μmol/L
or added at 0.1% w/w to standard rodent diet (Sniff
Spezialdiäten, Germany), respectively.
Cell culture experiments
Murine C2C12 myoblasts (CRL-1772, ATCC) were cultured in
DMEM (Lonza; Basel, Switzerland) supplemented with 10%
foetal calf serum (Gibco® Invitrogen, Carlsbad, CA). For induc-
tion of differentiation into myotubes, subconﬂuent cultures
were switched to DMEM containing 2% horse serum
(Sigma-Aldrich; Seelze, Germany). Thereafter, myotubes ﬁrst
underwent a single 2 h pre-treatment with increasing com-
pound concentrations (0.1 to 10 μmol/L, dissolved in DMSO)
or with an equal volume of DMSO, which was followed by the
addition of dexamethasone (10 μmol/L; DEX; Sigma-Aldrich;
Seelze, Germany) to the cell culture media for 24 h. Myotube
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diameter was then evaluated by image analysis software
(Analysis 3.0, Olympus Soft Imaging Solutions GmbH,
Münster, Germany). To determine cytotoxicity of selected
compounds, myoblasts or myotubes were incubated with in-
creasing concentrations for 24 h. Subsequently, the concen-
tration of lactate dehydrogenase activity was quantiﬁed in
the cell culture supernatant as a measure for cell destruction
as previously described.23
Animal experimentation
The animal experiments were approved by the
Regierungspräsidium Karlsruhe (35-9185.81/G-141/13) and
the Regierungspräsidium Leipzig (TVV 40/16). Three groups
of mice were included in this study, including (1) saline-
treated (sham; n = 20), (2) monocrotaline (MCT)-treated fed
a normal chow (MCT; n = 27), and (3) MCT-treated fed a
MuRF1 inhibitor chow (MCT + compound; n = 27). Brieﬂy,
C57BL/6 mice (aged 8 weeks) were subcutaneously injected
weekly with either MCT (600 mg/kg) or a matched volume
of saline for 6 weeks—a time period where MCT is known
to induce cardiac cachexia due to pulmonary hypertension
and subsequent RV dysfunction rather than anorexia.24 Mice
were exposed to identical conditions under a 12:12 h
light/dark cycle with food and water provided ad libitum.
The MCT + compound group started receiving the inhibitor
chow 1 week prior to the MCT injections, whereas the sham
and MCT groups were fed an identical chow but without the
addition of the selected compound. Body weight was re-
corded every week for each mouse. Mice were sacriﬁced fol-
lowing deep anesthetization with i.p. administration of
fentanyl (0.05 mg/kg), medetomidine (0.5 mg/kg), midazolam
(5 mg/kg), and ketamine (100 mg/kg). At sacriﬁce, the heart
and lungs were dissected, cleaned, blotted dry, and weighed,
with the heart ﬁxed in 4% PBS-buffered formalin. The left
tibialis anterior (TA), soleus, extensor digitorum longus
(EDL), and section of costal diaphragm were also dissected,
weighed, and ﬁxed in 4% PBS-buffered formalin, while the
remaining muscle portions were immediately frozen in liquid
N2 for molecular analysis. Muscle wet weights were normal-
ized to tibia length, which allowed a fair comparison of
relative changes in muscle mass between all groups due to
differences in body weight.
Contractile function
The left costal diaphragm muscle was prepared in a
Krebs–Hanseleit buffer solution (120.5 NaCl, 4.8 KCl, 1.2
MgSO4, 1.2 NaH2PO4, 20.4 NaHCO3, 1.6 CaCl2, 10 dextrose,
1 pyruvate; in mmol/L at a pH of ~7.4) at room temperature
equilibrated with 95% O2–5% CO2 for contractile measure-
ments. Brieﬂy, a muscle bundle connected from rib to central
tendon was dissected, attached to silk sutures (4-0) at either
end, and mounted vertically in a buffer-ﬁlled organ bath
(~22°C) for in vitro contractile function to be assessed using
a length-controlled lever system (301B, Aurora Scientiﬁc
Inc., Aurora, Canada), as previously described.25 The muscle
bundle was set at optimal length and after a 15 min
thermo-equilibration period was stimulated over a force–
frequency protocol between 1 and 300 Hz (600 mA; 500 ms
train duration; 0.25 ms pulse width). The muscle then
underwent a force–velocity protocol whereby the muscle
was allowed to shorten against external loads (80–10% of
the maximal tetanic force; each separated by 1 min) after
being stimulated at 150 Hz for 300 ms. Shortening velocity
was determined 10 ms after the ﬁrst change in length and
on the linear section of the transient (DMA software, Aurora
Scientiﬁc). Force (N) was normalized to muscle cross-
sectional area (CSA; cm2) by dividing muscle mass (g) by the
product of Lo (cm) and estimated muscle density (1.06),
which allowed speciﬁc force in N/cm2 to be calculated. Short-
ening velocity was normalized to optimal muscle length (in
Lo/s), while power was calculated for each load as the prod-
uct of shortening velocity and speciﬁc force (in W/cm2). A
total of 16 mice per group were assessed.
Tissue analyses
RNA isolation and quantiﬁcation of mRNA expression
Total RNA was isolated from C2C12 cells and reverse tran-
scribed into cDNA using random hexamers and Sensiscript
Reverse Transcriptase (Qiagen, Hilden, Germany). An aliquot
of the cDNA was used for quantitative RT-PCR, applying the
Light Cycler system (Roche Diagnostics, Mannheim,
Germany). The expression of speciﬁc genes was normalized
to the expression of hypoxanthin phosphoribosyltransferase
mRNA. For quantiﬁcation of MuRF1 expression, ﬂuorescence
resonance energy transfer technology was applied using the
following primers (TIB MolBiol, Berlin, Germany) and condi-
tions: hypoxanthin phosphoribosyltransferase: 50-CTCA
TggACTgATTATggACAggAC-30 and 50-gCAggTCAgCAAAgAACT
TATAgCC-30, 60°C annealing; MuRF1: 50-gATgTgCAAggAACA
CgAA-30, 50-CCTTCACCTggTggCTATTC-30, LC640-gCACAAggAg
CAAgTAggCACCTCAC-PH, 50-gCCTggTgAgCCCCAAACACCT-FL,
annealing 58°C.
Histology
The heart (medial section) and TA muscle were embedded in
parafﬁn; 3 μm sections were obtained, which where
mounted on slides and stained with haematoxylin and eosin.
Sections were than captured as images on a computer
connected to a microscope and subsequently evaluated using
Analysis software (Analysis 3.0, Olympus Soft Imaging Solu-
tions GmbH, Münster, Germany). RV wall thickness (in μm)
was determined from the mean of 10 individual
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measurements distributed along the free ventricular wall,
while mean ﬁbre CSA (in μm2) of the TA was evaluated after
assessment of approximately 300–500 ﬁbres per animal.
Proteomic and western blot analysis
Proteins from frozen diaphragm samples in sham, MCT, and
MCT + compound mice (n = 3 per group) were powdered
under liquid N2. Mass spectrometry was then performed at
the DZHK mass spectrometry core facility at Bad Nauheim
(for a detailed description, please refer to Konzer et al.26).
The relative ratios for MCT/sham and MCT + compound/
MCT were determined, with western blot used to further
study hits deemed as differentially expressed and highly sig-
niﬁcant (P < 0.01). The western blot analyses consisted of
frozen TA muscle samples being homogenized in relax buffer
(90 mmol/L HEPES, 126 mmol/L KCl, 36 mmol/L NaCl,
1 mmol/L MgCl, 50 mmol/L EGTA, 8 mmol/L ATP,
10 mmol/L creatine phosphate; pH 7.4) containing a
protease inhibitor mix (inhibitor mix M, Serva, Heidelberg,
Germany) and sonicated. Protein concentration was
determined (bicinchoninic acid assay, Pierce, Bonn,
Germany), and aliquots (5–20 μg) were separated by
SDS-polyacrylamide gel electrophoresis. Proteins were
transferred to a polyvinylidene ﬂuoride membrane and
incubated overnight at 4°C with the following primary
antibodies: MAFbx (1/2000, Eurogentec, Seraing, Belgium),
MuRF1 (1/1000, Myomedix Ltd., Neckargemünd, Germany),
CARP (1/500, Myomedix Ltd., Neckargemünd, Germany),
BAX (1/1000; Abcam, Cambridge, UK), eIF2B-delta (1/200;
Santa Cruz Biotechnolgy, Santa Cruz, USA), myosin heavy
chain (1/1000; Sigma-Aldrich, Taufkirchen, Germany), myosin
light chain (1/1000; Sigma-Aldrich, Taufkirchen, Germany),
sarcomeric actin (1/500; Sigma-Aldrich, Taufkirchen,
Germany), and ubiquitin (linkage-K48; 1/1000; Abcam, Cam-
bridge, UK). Membranes were subsequently incubated with
a horseradish peroxidase-conjugated secondary antibody
and speciﬁc bands visualized by enzymatic chemilumines-
cence (Super Signal West Pico, Thermo Fisher Scientiﬁc Inc.,
Bonn, Germany) and densitometry quantiﬁed using a 1D scan
software package (Scanalytics Inc., Rockville, USA). Blots were
then normalized to the loading control GAPDH (1/30 000;
HyTest Ltd., Turku, Finland). For proteasome activity in the cy-
tosolic fraction, muscle samples were homogenized in a
buffer containing 19 mM Tris (pH 7.5), 1 mM EDTA, 2 mM
ATP, 20% glycerol, and 4 mM DTT. Brieﬂy, chymotrypsin-like
activity was assayed using the ﬂuorogenic peptide Suc-LLVY-
7-amino-4-methylcoumarine (Biomol, Hamburg, Germany).
Proteins (20 μg) were incubated with reaction buffer
(0.05 mol/L Tris–HCl, pH 8.0, 0.5 mmol/L EDTA) and the la-
belled peptide (40 μmol/L), with the kinetics of the reaction
recorded using a spectroﬂuorometer (Tecan Saﬁr 2, Tecan,
Crailsheim, Germany) at an excitation of 380 nm and emis-
sion at 440 nm. Only the proportion of the reaction that
could be inhibited by MG132 (20 μmol/L, Sigma, Taufkirchen,
Germany) was regarded as chymotrypsin-like activity. For the
calculation of enzymatic activity, a calibration curve of free
amino-4-methylcoumarine (Sigma, Taufkirchen, Germany)
was recorded and values then determined as milliunits per
milligram protein. All data are presented as fold change rela-
tive to sham.
Statistical analyses
Data are presented as mean ± SEM. One-way analysis of
variance (ANOVA) followed by Bonferroni post hoc was used
to compare conditions in cell culture and animal experi-
ments, while two-way repeated measures ANOVA followed
by Bonferroni post hoc was used to assess muscle contractile
function in mice (GraphPad Prism). Signiﬁcance was accepted
as P < 0.05.
Results
In vitro selection of small molecules perturbing
MuRF1
Figure 1A provides a summary of the compound selection
scheme, which started with in vitro screenings for com-
pounds that inhibit MuRF1 central titin binding functions.
This scheme resulted in the compound EMBL ID#704946 be-
ing selected for our subsequent cell and mouse studies.
Brieﬂy, the in-house library of the Chemical Biology Core
Facility comprising 130 000 compounds from four commer-
cial suppliers was screened for inhibitors in the GST-MuRF1/
His6-titin AlphaScreen shown in Figure 1A–C. In total, 393
compounds with >35% inhibition at 40 μmol/L were selected
and tested in triplicate to conﬁrm their activity in the original
MuRF1 AlphaScreen and also the absence of activity in an
AlphaScreen with GSTHis as a negative control for speciﬁcity.
From these, 79 compounds with conﬁrmed MuRF1 activity
were reordered as fresh powder from the suppliers in 1 mg
scale to perform concentration–response titration experi-
ments. Using as selection criteria IC50 < 25 μmol/L, no or
low activity in the GSTHis counter assay, and availability from
the suppliers at 1 mg scale, we established a ﬁnal priority list
of nine compounds (‘top 9’). Top 9 compounds fulﬁlled the
following criteria: inhibition of MuRF1 central to titin
A168-170 interaction with IC50 < 25 μmol/L and the absence
in 12 other screens carried out by the EMBL core facility.
Next, we studied the effect of these identiﬁed nine com-
pounds on the E3 ligase activity of full-length MuRF1 con-
structs: The N-terminal ring ﬁnger domain in MuRF1
catalyses in vitro the ubiquitin transfer to titin A168-A170
(data not shown), or to itself (Figure 1D). Several compounds
decreased E3 ligase activity, both to titin and to MuRF1, while
others had little or no effect. In summary, we established
from a 130 000 compound screen a prioritized top 9
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Figure 1 An overview of the screening process that ﬁnally prioritized the compound EMBL ID#704946 in this study (A). An AlphaScreen of 130 000
compounds was ﬁrst performed, which resulted in 79 hits based on their ability to inhibit the interaction between titin and MuRF1’s ‘central domain’
(B–C). These interacting fragments were expressed as GST and His-tagged fusion proteins so that complex formation could be monitored in an
AlphaScreen assay with glutathione donor and Ni-NTA acceptor beads, respectively (C). Of these 79 compounds, a total of 9 were further synthesized
and tested for inhibition towards MuRF1 autoubiquitination (D), with 3 compounds (#704946, #704946-5, #704946-8) showing the greatest inhibition
(E). These ﬁnal three compounds were then tested for cytotoxicity in myoblasts (F) and myocytes (G), with increasing concentrations of ID#704946
clearly showing a lower activity in lactate dehydrogenase. Refer to text for further details. Data are presented as mean ± SEM.
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compound list with high MuRF1–titin speciﬁcity. Of these,
three compounds also inhibited MuRF1’s E3 ligase activities
(Figure 1D and 1E), and one compound (lane ID#704946)
had a low cytotoxicity towards C2C12 myoblasts or myotubes
(Figure 1F and 1G): At 25 μmol/L, the compound ID#704946
showed no apparent toxicity in C2C12 cells, whereas two
structurally related analogues (analogues #704946-5 and
#704946-8, respectively) were toxic for cells at lower concen-
trations. Therefore, subsequent cell and animal experiments
in this study were conducted with compound ID#704946.
In vitro effects of the MuRF1 inhibitor ID#704946
in dexamethasone-treated myotubes
Dexamethasone treatment induced an approximately 2-fold
increase in MuRF1 mRNA expression relative to untreated
cells (P < 0.05; Figure 2A). The addition of 10 μmol/L
#704946 to the culture medium attenuated this DEX-induced
increase in MuRF1 expression (for 10 μmol/L, P < 0.05; for
0.1 μmol/L, no signiﬁcant effect; Figure 2A). Myotube diame-
ter was also reduced in DEX-treated cells by 23% (P < 0.05;
Figure 2B), and while pre-incubation of myotubes with
0.1 μmol/L #704946 had no effect, a concentration of
10 μmol/L completely abolished ﬁbre atrophy (P < 0.05;
Figure 2B). Overall, therefore, our data indicated that
#704946 compound at 10 μmol/L in the culture medium
attenuated DEX-induced myotube atrophy, possibly due to
attenuating MuRF1 expression.
Mouse model of cardiac cachexia
Consistent with the literature,24 MCT injections over the
6 week period resulted in cardiac cachexia: Sham mice in-
creased body weight by 7.9 ± 0.8% compared with MCT mice
where a 0.7 ± 0.6% loss was observed (Figure 3A). In addition,
an increase in pulmonary congestion (Figure 3B), heart
weight (Figure 3C), and RV hypertrophy (Figure 3D and 3E)
was also present (all P < 0.05), which is consistent with the
development of pulmonary hypertension and subsequent
RV dysfunction. The observed weight loss was due, at least
in part, to a reduction in skeletal muscle mass, as wet weights
for the EDL (Figure 4A), soleus (Figure 4B), and TA (Figure 4C)
were all lower in MCT mice compared with shams. Speciﬁ-
cally, MCT mice had a reduction in TA muscle weight of
~10% (Figure 4C), and this was associated with a lower ﬁbre
CSA of ~20% (P < 0.05; Figure 4D and 4E). In addition, skele-
tal muscle contractile function was also impaired in MCT
mice: While no signiﬁcant effects were seen in isometric
forces (Figure 5A), the more clinically relevant measures of
shortening velocity (Figure 5B) and power (Figure 5C) were
impaired in MCT compared with sham mice, with peak values
for both reduced by ~20% (P < 0.05).
In vivo effects of the MuRF1 inhibitor in cardiac
cachexia
As our in vitro studies identiﬁed ID#704946 as having the
greatest inhibition of ubiquitin transfer (Figure 1E) in combi-
nation with the lowest toxicity (Figure 1F and 1G), while
further being able to lower MuRF1 expression and myotube
atrophy in DEX-treated C2C12 cells, we next tested the
effects of this compound in mice with cardiac cachexia
induced by MCT. MCT-treated mice fed with ID#704946
underwent the same pathophysiological alterations of cardiac
cachexia to that observed in the MCT mice on normal chow:
Pulmonary congestion was accompanied by right ventricular
hypertrophy, while weight gain was absent (Figure 3). In
marked contrast to MCT mice on normal chow, however,
ID#704946 feeding rescued TA from atrophy both with
respect to total muscle weight (Figure 4C) and ﬁbre CSA
Figure 2 Expression of MuRF1 at the mRNA level (A) and atrophy (B) was
elevated in myotubes following 24 h incubation with dexamethasone
(DEX; 10 μmol/L). In contrast, pre-treatment for 2 h with ID#704946 at
10 μmol/L (but not 0.1 μmol/L) reduced MuRF1 mRNA levels and
prevented ﬁbre atrophy. Data are presented as mean ± SEM. *P < 0.05
vs. CON.
§
P < 0.05 vs. DEX.
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(Figure 4D and 4E). We also observed effects in other skeletal
muscles in the ID#704946-fed mice, such that wet weights of
the EDL and soleus muscles in MCT + ID#704946 mice were
not statistically different to shams (Figure 4A and 4B). Impor-
tantly, ID#704946 feeding in MCT-treated mice was also able
to restore muscle contractile function, both with regards to
shortening velocity and power when compared with sham
mice (P < 0.05; Figure 5B and 5C). In summary, therefore,
our animal feeding experiments indicated that ID#704946
attenuated skeletal muscle wasting and dysfunction in car-
diac cachexia, with the most obvious effects noted in the
TA and diaphragm. As such, we performed subsequent mo-
lecular analyses on these muscle groups.
Effects of compound treatment on signalling and
contractile proteins
To gain insights into the apparent protective mechanisms of
ID#704946, we next analysed the proteomes from muscle
tissue in mice from each experimental group (Figure 6A
and 6B). Comparison of proteome data sets revealed 51
Figure 3 Physical characteristics of sham and mice treated with monocrotaline fed either normal chow (MCT) or EMBL ID#704946 compound
(MCT + 704946). Data conﬁrmed that MCT treatment induced cardiac cachexia independent of the chow administrated, as demonstrated by an im-
paired weight gain (A), increased pulmonary congestion (B), increased heart weight (C), and right ventricular (RV) hypertrophy (D), the latter visualized
by representative haematoxylin and eosin-stained sections (E). Data are presented as mean ± SEM, with n = 20 (sham), n = 27 (MCT), and n = 27
(MCT + 704946) per group. *P < 0.01 vs. sham.
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proteins from the MCT group and 70 proteins from the
MCT + compound group signiﬁcantly differentially expressed
(P < 0.01; Figure 6C), out of which 5 were normalized by
compound treatment and identiﬁed as positive hits
(P < 0.01; Figure 6C and 6D). Two of the identiﬁed hits were
suggestive of a protective mechanism: Reversal of MCT-
induced reduction in eIF2B (subunit δ) implies that
ID#704946 prevented dysregulation in protein translation,
while reversal of the MCT-induced increase in BAX by this
substance implies a protection from augmented apoptosis
in this cardiac cachexia model. To verify our mass spectrom-
etry screening data, we next performed western blots with
speciﬁc antibodies. This independent method conﬁrmed that
both eIF2B and BAX were normalized in compound-fed
animals: eIF2Bδ expression was signiﬁcantly reduced by 25%
in MCT mice compared with shams, but this was prevented
in mice fed by the compound, while conversely, BAX expres-
sion was signiﬁcantly increased by 103% in MCT mice com-
pared with shams, but this again was not observed in
MCT + compound mice (Figure 6E–G). While mass spectrom-
etry provides global unbiased overviews, low abundant pro-
teins are not displayed in whole proteome data sets.
Therefore, we also analysed protein expression of a number
of key signalling genes by western blots, including MuRF1
as well as MAFbx (another key E3 ligase), in order to conﬁrm
that the ID#704946 compound was speciﬁc to MuRF1, while
also quantifying CARP (a binding target of MuRF127). In sup-
port of our cell culture experiments, the immunoblots
Figure 4 Skeletal muscle wet weights (normalized to tibia length) for the EDL (A), soleus (B), and tibialis anterior (TA) (C). In addition, the ﬁbre cross-
sectional area for the TA muscle is also presented (D) and representative histological sections (E). Data are presented as mean ± SEM, with n = 20
(sham), 27 (MCT), and 27 (MCT + 704946) per group. *P < 0.05 vs. sham; §P < 0.01 vs. sham and MCT + ID#704946.
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revealed that the compound was able to down-regulate the
increased MuRF1 expression induced by cardiac cachexia
(P < 0.05; Figure 7A), whereas the expression of MAFbx
remained unchanged between groups (P > 0.05; Figure 7B).
In addition, the expression of the MuRF1 target CARP was
also normalized to sham values following treatment with
the compound (P > 0.05; Figure 7C).
We ﬁnally assessed also contractile proteins, because the
compound screen was designed in the ﬁrst place to perturb
recognition of myoﬁbrillar proteins by MuRF1: While the ex-
pression of myosin heavy and light chains were not different
between groups (P > 0.05; Figure 8A and 8B), we found sar-
comeric actin to be reduced in MCT mice compared with
shams by 14% (P < 0.05; Figure 8C). Depletion of sarcomeric
actin by MCT stress was prevented in mice treated with the
compound ID704946 (P > 0.05; Figure 8C). Consistent with
the idea that this compound can attenuate stress-induced
E3 ligase activities towards myoﬁbrillar proteins, we found
ubiquitinated actin to be elevated in MCT mice by 19%
(P < 0.05; Figure 8D), whereas mice treated with MCT and
the compound had only a 10% increase as compared with
shams (P > 0.05; Figure 8D). In line with these ﬁndings, pro-
teasome activity was shown to be up-regulated in the MCT
mice compared with both sham and MCT + compound mice
by ~30% (Figure 8F). Collectively, therefore, the combined
proteome, immunoblot, and activity data are consistent with
the notion that ID#704946 acts as a MuRF1 antagonist that
blunts ubiquitination and subsequent proteasome activity.
Discussion
Development of the MuRF1 inhibitor compound
Previous studies have reported that small-molecule knock-
downs of MuRF1 can prevent atrophy ex vivo in
myotubes.13–15 However, to our knowledge, this concept
had yet to be translated to an in vivo setting, such as animal
models that mimic clinically relevant disease conditions. It is
likely that a complete inhibition of MuRF1, such as blockade
of its ring ﬁnger functions or by gene inactivation, may be
detrimental as MuRF1 is suggested to have additional func-
tions beyond simply that of an atrogin.28 For example, MuRF1
knockout (KO) mice are much more susceptible to cardiac hy-
pertrophy,28 and patients with null mutations in the MuRF1
gene also suffer a similar fate,29 which indicates that basal
MuRF1 expression is required for myocyte homeostasis. In
addition, small molecules directed to the ubiquitin transfer
catalysing ring ﬁnger of MuRF1 might provide toxicity by lack
of target speciﬁcity and thus leading to protein aggre-
gates.18,27,30 Based on these considerations, we hypothesized
that small molecules inhibiting the MuRF1 interaction with
the giant ﬁlament titin may provide an alternative approach
towards perturbing the action of MuRF1 on myoﬁbrillar pro-
teins and myoﬁbril atrophy, but may leave MuRF1 basal ex-
pression in place. The MuRF1–titin compound screens used
Figure 5 In vitro skeletal muscle contractile function, as assessed during
isometric contractions (A) and also isotonic contractions, whereby short-
ening velocity (B) and power (C) were determined. MCT-treated mice
demonstrated impairments in shortening velocity and power by around
20% compared with shams, but this was essentially prevented in MCT
mice fed the ID#704946 compound. Data are presented as mean ± SEM,
with n = 16 per group. *P < 0.05 vs. sham; §P < 0.01 vs. sham and
MCT + ID#704946.
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Figure 6 The proteomes expressed in TA muscle samples were analysed using mass spectrometry to identify differentially expressed protein in the
different groups (n = 3 per group). (A, B) Differentially expressed proteins found in MCT/sham mice (A) and in MCT + ID#704946/MCT mice (B) are
shown by volcano plots. (C) The set of 51 differentially expressed proteins from group A and of 70 proteins from group B share a group of 5 proteins
that are differentially expressed in both sets with high signiﬁcance. We therefore consider them as candidates to be modulated by the ID#704946 com-
pound during MCT stress: These ﬁve proteins are detailed in the table (D). Of these, two proteins were further investigated by western blot (n = 9 per
group) including eIF2B subunit-delta (E) and BAX (F), with representative blots also presented (G). Data are presented as mean ± SEM. *P < 0.05 vs.
sham; §P < 0.01 vs. MCT.
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in the present study were developed along this rationale and
were able to identify nine compounds that fulﬁlled our
in vitro selection criteria (Figure 1). These novel identiﬁed
compounds (i.e. not FDA approved) were ﬁrst assessed for
toxicity prior to our animal experiments, with the compound
ID#704946 evidencing both the lowest toxicity in cultured
myotubes (Figure 1G) and also a rapid bioavailability in the
serum [i.e. 2 h after i.p. injection in a linear dose–serum
concentration relationship, as determined by liquid chroma-
tography coupled with mass spectrometry; data not shown].
Taken together, therefore, the selected compound fulﬁlled
the entry criteria for our animal experiments, which included
inhibiting the MuRF1–titin interaction, inhibiting MuRF1 E3
ligase activity, showing least apparent toxicity in cultured
myotube assays, and also protecting myotubes from
DEX-induced atrophy.
Effects of in vivo MuRF1 inhibition on cardiac
cachexia
For in vivo studies with the ID#704946 compound, we
stressed mice with the alkaloid MCT such that weekly i.p. in-
jections induced pulmonary hypertension, right ventricular
dysfunction, and subsequent cardiac cachexia over a 6 week
period.24 Clinical indices (i.e. pulmonary congestion, heart
Figure 7 Protein expression and representative blots for MuRF1 (A), MAFBx (B), and CARP (C) for sham, MCT, and MCT + ID#704946 mice. Our data
revealed that MCT treatment leads to an increase in MuRF1 and CARP expression, but this was attenuated in mice fed the #704946 compound. No
changes were detected in the levels of MAFBx. Data are presented as mean ± SEM, with n = 12–16 per group. *P < 0.05 vs. sham and
MCT + ID#704946.
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weight, RV hypertrophy, and weight gain) were near identical
between the MCT and MCT + compound-fed mice, which sug-
gest that disease severity progressed similarly in both groups
independent of compound feeding. Importantly, however,
while MCT-treated mice showed a progressive loss of skeletal
muscle mass, the MCT + compound-fed mice did not follow
this trend and were protected with the most obvious effect
seen in the TA muscle. Interestingly, despite muscle atrophy
being attenuated in the MCT mice treated with compound
compared with normal chow, body weights between groups
remained similar. This is likely explained by body weight
(which was ~21 g in our mice) providing a gross measure that
is simply too insensitive to detect subtle changes (in mg) of
muscle mass, or alternatively, it may be related to reductions
in muscle mass being masked by concomitant increases in fat
mass and/or ﬂuid retention—a point the present study can-
not conﬁrm. To provide a direct functional assessment, we
also measured contractility in diaphragm muscle ﬁbres and
Figure 8 Protein expression for the contractile proteins myosin heavy (A) and light chains (B), sarcomeric actin (C), as well as ubiquitinated actin (D),
with the respective representative blots also presented (E) for sham, MCT, and MCT + ID#704946 mice. In addition, proteasome activity was also mea-
sured in each group (F). Data are presented as mean ± SEM, with n = 12–16 per group. *P < 0.05 vs. sham and MCT + ID#704946.
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observed that contractile dysfunction (in terms of shortening
velocity and power) induced by cardiac cachexia was essen-
tially prevented in mice fed the ID#704946 compound. Col-
lectively, therefore, these two ﬁndings suggest that the
selective inhibition of MuRF1 by ID#704946 mediated a ben-
eﬁt to both skeletal muscle quantity (i.e. mass) and quality
(i.e. contractile function) in cardiac cachexia.
Signalling pathways underlying the MuRF1
inhibitor compound
Clearly, further studies are warranted to identify the mecha-
nism(s) in detail by which the compound ID#704946 medi-
ated its beneﬁts in the MCT-stressed mice (i.e. on
maintaining contractile function and muscle mass). Here,
for an initial overview, the present study included an unbi-
ased proteome proﬁling survey. The expression levels of ﬁve
proteins were found to speciﬁcally respond to the compound,
as indicated by comparison of the MCT and MCT + ID#704946
proteomes (Figure 6). This included an up-regulation of eIF2B
(subunit δ) and down-regulation of BAX, which we later con-
ﬁrmed by immunoblotting. The eIF2B pathway is a known
translational regulator of protein synthesis, with evidence
showing that its content can directly inﬂuence ﬁbre size.31
The direct targeting of elF2B by MuRF1 appears plausible be-
cause our previous yeast two-hybrid screens identiﬁed elF2B
as a MuRF1 interacting factor, linking MuRF1 as a negative
regulator of protein synthesis.32 In line with a direct regula-
tion of protein translation by MuRF1, injection of
D5-phenylalanine into MuRF1 KO mice demonstrated an ele-
vated muscle protein translation,27 while MuRF1 KO mice are
protected against a reduction in protein synthesis following
DEX treatment.11 As such, we suggest that MuRF1 mediated
a depletion of the translation initiation factor elF2B under
MCT stress, and this was relieved by the compound. Whether
this functionally accounts for the maintenance of muscle
mass remains to be determined, but this obviously warrants
further investigation. In addition, the compound also modu-
lated the pro-apoptotic regulator BAX, with this protein up-
regulated in MCT mice compared with shams and normalized
in MCT + ID#704946 mice. In human patients with chronic
heart failure, apoptosis is increased in skeletal muscle, and
this closely correlates to the degree of atrophy.33,34 Indeed,
it has been noted before that BAX is elevated in cardiac
cachexia and associated with an increased MuRF1 expres-
sion.35,36 Therefore, future studies are warranted to deter-
mine if MuRF1 inhibition by ID#704946 provides anti-
apoptotic signals in a muscle-speciﬁc fashion.
In line with our in vitro studies, we also conﬁrmed that the
increased protein expression of MuRF1 in MCT mice was
prevented by the compound, while no effects were noted
for the other apparent key atrogin MAFBx. Therefore, the
underlying mechanism of the compound appears to be
MuRF1 speciﬁc, which would be expected based on our pre-
liminary in vitro studies. However, it still remains unclear
whether the main effects of the compound in vivo are
exerted by the inhibition of MuRF1’s enzyme activity or
rather its down-regulation in protein expression, although
our in vitro and in vivo data suggest that a combination of
both is likely playing a role. MuRF1 is also known to interact
with numerous substrates, with one in particular being CARP
(a member of the muscle ankyrin repeat protein family20,37),
which is a purported nuclear-based and sarcomere (titin)-
based protein with transcriptional functions.20,37 CARP is
known to be up-regulated in stress-related conditions and is
associated with contractile dysfunction and muscle atro-
phy.20,38,39 In line with such evidence, we also observed an in-
crease in CARP expression in MCT-stressed mice, but this
effect was abolished in the ID#704946-fed mice. This suggests
that this compound may blunt CARP expression via its inhibi-
tion on MuRF1, which, in turn, may contribute to the mainte-
nance of muscle mass and function. Importantly, additional
experiments also provided evidence that the compound was
able to prevent the reduction in both the content and
ubiquitination of the key sarcomeric protein actin and a corre-
sponding signiﬁcant reduction in the activity of the ubiquitin
proteasome pathway. Interestingly, while myosin heavy chain
is generally suggested to be the key target of MuRF1-
mediated degradation,6,15 other studies have also found that
actin is similarly susceptible40: In vitro and in vivo data have
demonstrated lower protein content in line with a greater
ubiquitination of actin in catabolic conditions, with MuRF1
found to interact with and polyubiquitinate actin. As such,
our data provide strong support that the developed com-
pound was able to perturb the myoﬁbril-directedMuRF1 atro-
phy axis, which, in turn, inhibited actin ubiquitination and
degradation and thus overall muscle proteolysis.
Clinical considerations
The treatment of cardiac cachectic patients using compounds
naturally requires long-term interventions, raising concerns
on their potential cardiac and general toxicity. In this study,
we used high doses (about 3 mg per day per mouse) over a
6 week period. Therefore, it is next mandatory to further
evaluate in detail in vivo toxicities. Currently, we are monitor-
ing closely ID#704946 and other structurally related
compounds for their effects on cardiac remodelling and for
bioavailability by liquid chromatography coupled with mass
spectrometry. Clearly, this study provides only a starting point
because all of the top 9 compounds are novel and
uncharacterized with regards to their toxicity and pharmacol-
ogy. Importantly, all steps involved in their selection can be
adapted to high-throughput approaches. Therefore, future
studies will aim to further expand the MuRF1 central–titin in-
hibitor compound line and in parallel to optimize individual
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hits such as ID#704946, to test whether such compounds can
be translated to treat stress-induced myopathic pathologies.
Conclusions
Our data show that a novel compound (ID#704946) selected
for its inhibition of the muscle-speciﬁc E3 ligase MuRF1 was
able to attenuate in vivo skeletal muscle atrophy and contrac-
tile dysfunction in a mouse model of cardiac cachexia. These
ﬁndings were further supported by our in vitro experiments,
whereby myotube atrophy induced by the synthetic glucocor-
ticoid DEX was abolished following treatment with the
ID#704946 compound. The compound-induced attenuation
of muscle wasting both in vivo and in vitro was associated
with reduced levels of MuRF1 expression, while additional
proteome analyses revealed a protection of de novo protein
synthesis and a down-regulation in apoptosis.
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